Article Text

Download PDFPDF
Radiation Therapy for Recurrent Clear-Cell Cancer of the Ovary
  1. Gina L. Westhoff, MD,
  2. Katherine C. Fuh, MD, PhD,
  3. Terry A. Longacre, MD,
  4. Jennifer Leah McNally, MD,
  5. I-Chow Hsu, MD,
  6. Daniel S. Kapp, MD, PhD,
  7. Nelson Teng, MD, PhD and
  8. Lee-may Chen, MD
  1. * Division of Gynecologic Oncology, Legacy Health, Portland, OR;
  2. Division of Gynecologic Oncology, Washington University School of Medicine, St. Louis, MO;
  3. Department of Pathology, Stanford University School of Medicine, Stanford;
  4. § Division of Gynecologic Oncology and
  5. Department of Radiation Oncology, University of California San Francisco, San Francisco; and
  6. Department of Radiation Oncology and
  7. # Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, CA.
  1. Address correspondence and reprint requests to Lee-may Chen, MD, University of California San Francisco, 550 16th St, 7th Floor, Box 0132, San Francisco, CA 94143. E-mail: Lee-may.chen{at}ucsf.edu.

Abstract

Objective Given the relative chemo-resistant nature of clear-cell gynecologic cancers, we investigated the utility of radiation therapy (RT) to treat recurrent clear-cell carcinoma (CCC) of the ovary.

Methods A retrospective chart review of patients with recurrent CCC managed from 1994–2012 was conducted at 2 academic medical centers. Demographic and clinicopathologic factors were abstracted and evaluated using Pearson χ2 or t tests, Kaplan-Meier and Cox regression analyses.

Results Fifty-three patients had recurrent CCC, and 24 (45.3%) of these patients received RT. There were no significant differences in age, stage, optimal cytoreduction, platinum response, or the percentage of patients that received more than 3 regimens of chemotherapy between the 2 groups. Patients who received RT for recurrent CCC were more likely to have had a focal recurrence (62.5% vs 10.3%, P ≤ 0.001) and to have undergone secondary cytoreduction (70.8% vs 10.3%, P ≤ 0.001). Of patients who received RT, 73.9% underwent surgery with or before their treatment. Five-year survival after recurrence was significantly higher in the group that received RT, 62.9% versus 18.8% (P = 0.002). In a multivariate analysis, platinum-sensitive disease and RT were associated with improved survival from recurrence, (hazard ratio, 0.26; 95% confidence interval, 0.08-0.81; P = 0.02 and hazard ratio, 0.28; 95% confidence interval, 0.09–0.90, P = 0.03, respectively).

Conclusions In this cohort of patients with recurrent CCC, platinum-sensitive disease and RT are associated with improved survival. However, it is important to note that the majority of these patients underwent surgery along with RT, and it may be that the benefit of RT is limited to those who undergo secondary cytoreduction.

  • Clear cell
  • Ovarian carcinoma
  • Radiation therapy
  • Recurrent

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.